Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Deere & Company (DE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Deere & Company — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Deere & Company trades at $616.53 (market cap $164.47B). The key difference: Deere & Company is far larger — about 32.5× ACADIA Pharmaceuticals Inc.'s market cap, and Deere & Company pays a 1.06% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DE | |
|---|---|---|
Market Cap | $5.06B | $164.47B |
Sector | Health | Industrials |
52-Week High | $29.39 | $662.49 |
52-Week Low | $20.06 | $439.11 |
Enterprise Value | $4.18B | $219.29B |
Dividend Yield | — | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
Deere & Company (DE) trades at $620.83, up 0.97% for the day, with a bullish technical outlook supported by moving averages and recent earnings beats. Revenue declined to $44.67B in 2025, but net income margins remain healthy at 10.33%. The stock is near its pivot point of $620, with support at $613 and resistance at $628. Analyst consensus is a Moderate Buy with a $676.08 price target, reflecting optimism despite cyclical headwinds in agricultural equipment demand.
The outlook is cautiously positive, driven by consistent earnings outperformance and strong institutional holdings, but investors face risks from revenue volatility and high debt levels. The stock offers value if agricultural recovery materializes, but macroeconomic sensitivity warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
